# Life Biosciences

its lead candidate ER-100 (AAV2-OSK) is in Phase I clinical trials for optic neuropathies, described as the first-ever epigenetic restoration candidate approved for clinical trials, with a related OSK gene therapy also approved for glaucoma eye trials.

Source: https://en.bioecon.ru/companies/life-biosciences/
Updated: 2026-07-20

- Country: United States

## Technologies

- [Partial epigenetic reprogramming](https://en.bioecon.ru/technology/partial-epigenetic-reprogramming/)